Lanzhou Foci Pharmaceutical Co., Ltd. (002644.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 8.29

From 52W high−18.36%

Volume5.33M

Market capCNY 4.18B

P/E (TTM)84.9x

P/S (TTM)4.6x

Div yield0.24%

Key dataSep 18, 2026

Open

CNY 8.29

From 52W high

−18.36%

Volume

5.33M

Market cap

CNY 4.18B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

29.6x

P/E (TTM)

84.9x

RSI (14)

45.5

MomentumView details →

1D Return

−0.24%

YTD Return

−5.21%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

84.9x

EV/EBITDA

29.6x

EV/Sales

4.0x

P/S (TTM)

4.6x

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

34.75%

Net Margin

5.76%

EBITDA Margin

13.58%

ROE (TTM)

2.84%

ROA (TTM)

2.05%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

−1.20%

EPS YoY

−14.03%

FCF YoY

+397.16%

Revenue CAGR 3Y

−4.23%

EPS CAGR 3Y

−23.20%

EBITDA YoY

—

MomentumView details →

1D Return

−0.24%

YTD Return

−5.21%

1Y Return

−6.83%

RSI (14)

45.5

vs 50D SMA

+0.33%

vs 200D SMA

−2.13%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.04x

Quick Ratio

2.39x

Div Yield

0.24%

Div Rate

CNY 0.02

Div Growth 1Y

+66.67%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

910.98M

Net Income (TTM)

52.49M

Op. CF (TTM)

231.83M

Latest newsMore news →

The indirect controlling shareholder of Foci Pharmaceutical changed to Gansu Pharmaceutical Group during the reporting period, while the controlling shareholder remained unchanged.32d ago

Foci Pharmaceutical announced its 2026 first-half results with revenue of 440 million yuan, up 2.55% year-on-year, and net profit attributable to shareholders of 39.74 million yuan, up 32.00%.32d ago

Similar companies

新劲刚300629.SZ 太力科技301595.SZ 康盛股份002418.SZ 鲁阳节能002088.SZ 凯中精密002823.SZ 神宇股份300563.SZ Find similar companies →

Latest newsMore news →

The indirect controlling shareholder of Foci Pharmaceutical changed to Gansu Pharmaceutical Group during the reporting period, while the controlling shareholder remained unchanged.32d ago Foci Pharmaceutical announced its 2026 first-half results with revenue of 440 million yuan, up 2.55% year-on-year, and net profit attributable to shareholders of 39.74 million yuan, up 32.00%.32d ago